sxsw

Breaking News: PTV Announces Featured Session at SXSW 2017

Austin, TX – October 17, 2016 – After several months of behind the scenes work, PTV is very excited to announce the selection of its panel as a Featured Session in the SXSW 2017 programming lineup. These high-profile “main stage” sessions spotlight key people and trends germane to the SXSW community.

sxsw-2017

Collaborative Innovation in the Digital Health Age
Personalized medicine. Artificial intelligence. Cognitive computing. In our increasingly interconnected world, the future of healthcare can at times read more like a Gene Roddenberry story than, well, the future. Moderated by Austin’s own Dr. Clay Johnston, join Johnson & Johnson and IBM’s top executives as the consumer wellness and big data giants discuss cross-industry partnerships and the convergence of health and IT that’s delivering improved health outcomes and transforming the patient experience. Presented by PTV Healthcare Capital, speakers include Alex Gorsky, Chairman & CEO of Johnson & Johnson; Ginni Rometty, Chairman, President, and CEO of IBM Corporation; and Dr. Clay Johnston, Dean of UT Austin’s Dell Medical School.

Be on the lookout for more news in the coming months!

About SXSW Conference
Featuring a variety of tracks that allow attendees to explore what’s next in the worlds of entertainment, culture, and technology, SXSW proves that the most unexpected discoveries happen when diverse topics and people come together.

Explore KeynotesFeatured Speakers, and programming tracks below. Stay tuned to SXSW News for the latest 2017 SXSW Conference announcements and updates throughout the season.

Download the SXSWeek Timeline for a quick reference to our 2017 Schedule and daily programming overview.

About PTV
PTV is a healthcare venture capital and growth equity firm dedicated to enabling healthcare entrepreneurs and global innovation. It is comprised of a highly collaborative team of professionals, deeply experienced as investors and operators of life science companies. PTV focuses on mid-to-late stage companies with comparatively low technical, regulatory, and financial risk that are “with the grain” of healthcare economics – improving patient outcomes while decreasing costs – in markets with significant unmet clinical needs.